Literature DB >> 10782682

QSAR of 1,1'-(1,2-ethylenebisbenzyl)bis(4-substitutedpyridinium) dibromides as choline kinase inhibitors: a different approach for antiproliferative drug design.

J Campos1, M C Núñez, V Rodríguez, M A Gallo, A Espinosa.   

Abstract

Ten new structures of a series of the title compounds were synthesized and screened for their activity to inhibit choline kinase under ex vivo conditions. Their inhibitory potency correlates with the 13C chemical shifts (in CD3OD) of the methylene group bearing the positively charged nitrogen. The inhibitory effect on proliferation against the HT-29 cell line is strongly dependent on its ability to inhibit the production of phosphorylcholine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10782682     DOI: 10.1016/s0960-894x(00)00080-9

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

1.  Phosphorylation of the yeast choline kinase by protein kinase C. Identification of Ser25 and Ser30 as major sites of phosphorylation.

Authors:  Mal-Gi Choi; Vladlen Kurnov; Michael C Kersting; Avula Sreenivas; George M Carman
Journal:  J Biol Chem       Date:  2005-05-25       Impact factor: 5.157

2.  Crystal structures of human choline kinase isoforms in complex with hemicholinium-3: single amino acid near the active site influences inhibitor sensitivity.

Authors:  Bum Soo Hong; Abdellah Allali-Hassani; Wolfram Tempel; Patrick J Finerty; Farrell Mackenzie; Svetoslav Dimov; Masoud Vedadi; Hee-Won Park
Journal:  J Biol Chem       Date:  2010-03-18       Impact factor: 5.157

3.  A facile synthesis of 3-substituted 9H-pyrido[3,4-b]indol-1(2H)-one derivatives from 3-substituted beta-carbolines.

Authors:  Guowu Lin; Yue Wang; Qingfa Zhou; Weifang Tang; Jian Wang; Tao Lu
Journal:  Molecules       Date:  2010-08-17       Impact factor: 4.411

Review 4.  Choline Kinase: An Unexpected Journey for a Precision Medicine Strategy in Human Diseases.

Authors:  Juan Carlos Lacal; Tahl Zimmerman; Joaquín M Campos
Journal:  Pharmaceutics       Date:  2021-05-25       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.